Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001050433 | SCV001214540 | uncertain significance | Gastrointestinal stromal tumor | 2022-08-16 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 846986). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 672 of the PDGFRA protein (p.Ile672Val). |
| Baylor Genetics | RCV003473641 | SCV004200947 | uncertain significance | Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal | 2023-07-19 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV004031564 | SCV005024530 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-06 | criteria provided, single submitter | clinical testing | The p.I672V variant (also known as c.2014A>G), located in coding exon 14 of the PDGFRA gene, results from an A to G substitution at nucleotide position 2014. The isoleucine at codon 672 is replaced by valine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |